Dietary advanced glycation end-products exacerbate sarcopenia onset by activating apoptosis through PRMT1-mediated

Tian-Jin Huang1,2, Shu Shang1,2, Qin Wan1,2

  • 1Department of Geriatrics, Jiangxi Provincial People's Hospital, No. 92 Aiguo Rd, Donghu District, Nanchang, Jiangxi, 330006, China.

Abstract

Insights

Dietary advanced glycation end-products (AGEs) accelerate sarcopenia by activating PRMT1, which methylates CRTC3, leading to muscle cell apoptosis. Inhibiting PRMT1 or Bax shows therapeutic potential for age-related muscle loss.

Area of Science:

  • Gerontology
  • Molecular Biology
  • Biochemistry

Background:

  • Sarcopenia, a decline in muscle mass and function, is a significant health concern for the elderly.
  • Dietary advanced glycation end-products (AGEs) are linked to sarcopenia, but the underlying molecular mechanisms are not fully understood.

Purpose of the Study:

  • To elucidate the molecular mechanisms by which dietary AGEs contribute to sarcopenia.
  • To identify potential therapeutic targets for mitigating AGE-induced muscle aging.

Main Methods:

  • Established a mouse model of sarcopenia via a high AGE diet.
  • Utilized grip strength and rotarod tests for functional assessment.
  • Employed proteomics, immunoprecipitation, mass spectrometry, qPCR, and Western blotting to analyze protein interactions and expression.

Main Results:

  • Dietary AGEs accelerated sarcopenia by inducing apoptosis in muscle cells.
  • Protein arginine methyltransferase 1 (PRMT1) was upregulated and mediated CRTC3 methylation at R534.
  • Activated CRTC3 and FOXO3a transactivated BAX, promoting apoptosis and muscle atrophy.
  • Inhibition of PRMT1 or Bax attenuated AGE-induced sarcopenia in vitro and in vivo.

Conclusions:

  • PRMT1-mediated CRTC3 arginine methylation is a key pathway in AGE-induced sarcopenia.
  • Targeting PRMT1 or the Bax signaling pathway offers a potential therapeutic strategy for sarcopenia.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
Overview of Protein Metabolism01:21

Overview of Protein Metabolism

Proteins are broken down into amino acids during digestion. Unlike fats and carbohydrates, which are stored for later use, proteins are not. Instead, amino acids are either used to produce ATP through oxidation or contribute to the creation of new proteins for the growth and repair of the body. Any surplus amino acids from the diet are converted into glucose or triglycerides rather than excreted.
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
605
Regulated Protein Degradation02:58

Regulated Protein Degradation

It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
7.1K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.3K
Protein Modifications in the RER01:26

Protein Modifications in the RER

Modification of secretory and transmembrane proteins entering the rough ER begins in the ER lumen. These modifications aid in protein folding and stabilize the acquired tertiary structure. Protein modifications in the rough ER co-occur at different stages of protein folding.
Broadly, these modifications can be categorized into four main categories — glycosylation, formation of disulfide bonds, assembly of protein subunits, and specific proteolytic cleavages like removal of signal...
4.9K
The Proteasome02:18

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
8.4K